Amarin Corporation plc
New Jersey, United States · Biotechnology, Health Care, Pharmaceutical
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide.
Key facts
- Headquarters
- New Jersey, United States
- Employees
- 457
- Industries
- Biotechnology, Health Care, Pharmaceutical
- Status
- Private
- Website
- amarincorp.com
- Company page
Recent activity at Amarin Corporation plc
- : Amarin Corporation plc announces national reimbursement approval for VAZKEPA® in Italy to reduce cardiovascular risk in high-risk patients.
- : Amarin Corporation plc appoints Peter Fishman as Chief Financial Officer
- : Amarin Corporation plc Names Aaron Berg as President and Chief Executive Officer (CEO)
- : Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
- : Amarin Appoints Patrick Holt as President and Chief Executive Officer
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Leadership
- Peter Fishman, Chief Financial Officer
- Aaron Berg, President
- Jonathan Provoost, Chief Legal & Compliance Officer
Verified email and direct lines for Amarin Corporation plc’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Amarin Corporation plc in the news
- AMRN - Amarin Corp ADR Stock Price and Quote - Finviz (May 26, 2026)
- Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026 - Yahoo Finance (Oct 21, 2026)
- Amarin Highlights New Data on Lipoprotein(a) and other Apolipoprotein B Containing Lipoproteins at American Heart Association (AHA) Scientific Sessions 2026 - The Manila Times (Nov 09, 2026)
- AMRN: Amarin Corp - ADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits (Dec 16, 2011)
- Results from the Vascepa® (icosapent ethyl) cardiovascular outcomes REDUCE-IT™ - MultiVu (Nov 10, 2018)
- A colorectal cancer trial missed its goal, but estimated 5-year survival was 62% with the drug versus 45% with placebo. - Stock Titan (Oct 25, 2026)
- Amarin Corporation plc (AMRN) Company Profile & Facts - Yahoo Finance - Yahoo! Finance Canada (May 20, 2017)
- Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk - MultiVu (Dec 13, 2019)
Companies similar to Amarin Corporation plc
- Medisca · Biotechnology, Health Care, Pharmaceutical
- Halozyme Therapeutics · Biotechnology, Health Care, Pharmaceutical
- Petauri · Biotechnology, Health Care, Pharmaceutical
- Hanmi Pharmaceutical Ltd · Biotechnology, Health Care, Pharmaceutical
- Acadia Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical
About Amarin Corporation plc: questions and answers
What does Amarin Corporation plc do?
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide.
Where is Amarin Corporation plc headquartered?
Amarin Corporation plc is headquartered in New Jersey, United States.
How many employees does Amarin Corporation plc have?
Amarin Corporation plc has about 457 employees.
Who leads Amarin Corporation plc?
Aaron Berg is a President at Amarin Corporation plc.
What is the latest news on Amarin Corporation plc?
On Dec 16, 2024, Amarin Corporation plc announces national reimbursement approval for VAZKEPA® in Italy to reduce cardiovascular risk in high-risk patients.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy